Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients

Tereza Martinu; David N Howell; Scott M Palmer

doi:10.1055/s-0030-1249113

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2010; 31(2): 179-188
DOI: 10.1055/s-0030-1249113

Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients

Tereza Martinu¹ , David N. Howell² , Scott M. Palmer¹

¹Department of Medicine, Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina
²Department of Pathology, Duke University Medical Center, Durham, North Carolina

Abstract

ABSTRACT

Despite the recent development of many new immunosuppressive agents for use in transplantation, acute cellular and humoral rejection represent extremely prevalent and serious complications after lung transplantation. Acute cellular rejection, defined as perivascular or bronchiolar mononuclear inflammation, affects over 50% of lung transplant recipients within the first year. Furthermore, the frequency and severity of acute rejections are the most important risk factors for the subsequent development of bronchiolitis obliterans syndrome (BOS), a condition of progressive airflow obstruction that severely limits survival after lung transplantation. Treatment options for cellular rejection include high-dose methylprednisolone, antithymocyte globulin, or alemtuzumab. Emerging evidence also suggests that humoral rejection occurs in lung transplantation, characterized by local complement activation or the presence of antibody to donor human leukocyte antigens and is associated with an increased risk for BOS. Treatment options for humoral rejection include intravenous immunoglobulin, plasmapheresis, or rituximab. Herein, we review the clinical presentation, diagnosis, mechanisms, and treatment of cellular and humoral rejection after lung transplantation.

KEYWORDS

Lung transplantation - acute rejection - humoral rejection - antibody-mediated rejection

Volltext

Referenzen

REFERENCES

1 Trulock E P, Christie J D, Edwards L B et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant. 2007; 26 782-795
2 Sharples L D, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002; 21 271-281
3 Snyder L D, Palmer S M. Immune mechanisms of lung allograft rejection. Semin Respir Crit Care Med. 2006; 27 534-543
4 Colvin R B, Smith R N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol. 2005; 5 807-817
5 De Vito Dabbs A, Hoffman L A, Iacono A T, Zullo T G, McCurry K R, Dauber J H. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation?. Heart Lung. 2004; 33 372-380
6 Van Muylem A, Mélot C, Antoine M, Knoop C, Estenne M. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax. 1997; 52 643-647
7 Gotway M B, Dawn S K, Sellami D et al.. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology. 2001; 221 207-212
8 Shitrit D, Izbicki G, Fink G et al.. Late postoperative pleural effusion following lung transplantation: characteristics and clinical implications. Eur J Cardiothorac Surg. 2003; 23 494-496
9 Stewart S, Fishbein M C, Snell G I et al.. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007; 26 1229-1242
10 Hopkins P M, Aboyoun C L, Chhajed P N et al.. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant. 2002; 21 1062-1067
11 Trulock E P, Ettinger N A, Brunt E M, Pasque M K, Kaiser L R, Cooper J D. The role of transbronchial lung biopsy in the treatment of lung transplant recipients: an analysis of 200 consecutive procedures. Chest. 1992; 102 1049-1054
12 Chakinala M M, Ritter J, Gage B F et al.. Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant. 2004; 23 1396-1404
13 Reynaud-Gaubert M, Thomas P, Gregoire R et al.. Clinical utility of bronchoalveolar lavage cell phenotype analyses in the postoperative monitoring of lung transplant recipients. Eur J Cardiothorac Surg. 2002; 21 60-66
14 De Soyza A, Fisher A J, Small T, Corris P A. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med. 2001; 164 1209-1212
15 Silkoff P E, Caramori M, Tremblay L et al.. Exhaled nitric oxide in human lung transplantation: a noninvasive marker of acute rejection. Am J Respir Crit Care Med. 1998; 157(6 Pt 1) 1822-1828
16 Kowalski R J, Post D R, Mannon R B et al.. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006; 82 663-668
17 Bhorade S M, Janata K, Vigneswaran W T, Alex C G, Garrity E R. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant. 2008; 27 990-994
18 Huang Y, Nizami Nazih Zuhdi I. Correlation of Cylex ImmuKnow assay with lung allograft biopsy [abstract]. J Heart Lung Transplant. 2007; 26 S175
19 Yousem S A, Martin T, Paradis I L, Keenan R, Griffith B P. Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts?. Hum Pathol. 1994; 25 525-529
20 Reams B D, Musselwhite L W, Zaas D W et al.. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007; 7 2802-2808
21 Colombat M, Groussard O, Lautrette A et al.. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection: clinicopathologic correlations during the first 6 months after lung transplantation. Hum Pathol. 2005; 36 387-394
22 Chakinala M M, Ritter J, Gage B F et al.. Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant. 2005; 24 652-657
23 Stephenson A, Flint J, English J et al.. Interpretation of transbronchial lung biopsies from lung transplant recipients: inter- and intraobserver agreement. Can Respir J. 2005; 12 75-77
24 Burton C M, Iversen M, Scheike T, Carlsen J, Andersen C B. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation. 2008; 85 547-553
25 DeVito Dabbs A, Hoffman L A, Iacono A T et al.. Pattern and predictors of early rejection after lung transplantation. Am J Crit Care. 2003; 12 497-507
26 Hachem R R, Khalifah A P, Chakinala M M et al.. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005; 80 1406-1413
27 Kim D W, Dacic S, Iacono A, Grgurich W, Yousem S A. Significance of a solitary perivascular mononuclear infiltrate in lung allograft recipients with mild acute cellular rejection. J Heart Lung Transplant. 2005; 24 152-155
28 Glanville A R, Aboyoun C L, Havryk A, Plit M, Rainer S, Malouf M A. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008; 177 1033-1040
29 Scholma J, Slebos D J, Boezen H M et al.. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med. 2000; 162 2221-2225
30 Schulman L L, Weinberg A D, McGregor C, Galantowicz M E, Suciu-Foca N M, Itescu S. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med. 1998; 157(6 Pt 1) 1833-1837
31 Quantz M A, Bennett L E, Meyer D M, Novick R J. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant. 2000; 19 473-479
32 Treede H, Klepetko W, Reichenspurner H Munich and Vienna Lung Transplant Group et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant. 2001; 20 511-517
33 Hachem R R, Yusen R D, Chakinala M M et al.. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant. 2007; 26 1012-1018
34 Kumar D, Erdman D, Keshavjee S et al.. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005; 5 2031-2036
35 Garantziotis S, Howell D N, McAdams H P, Davis R D, Henshaw N G, Palmer S M. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001; 119 1277-1280
36 Zheng H X, Burckart G J, McCurry K et al.. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant. 2004; 23 541-546
37 Zheng H X, Zeevi A, McCurry K et al.. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol. 2005; 14 37-42
38 Palmer S M, Burch L H, Trindade A J et al.. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005; 171 780-785
39 Palmer S M, Klimecki W, Yu L et al.. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant. 2007; 7 693-699
40 Ibrahim J E, Sweet S C, Flippin M et al.. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. J Heart Lung Transplant. 2002; 21 311-318
41 Scott J P, Whitehead B, de Leval M et al.. Paediatric incidence of acute rejection and obliterative bronchiolitis: a comparison with adults. Transpl Int. 1994; 7(Suppl 1) S404-S406
42 Mahidhara R, Bastani S, Ross D J et al.. Lung transplantation in older patients?. J Thorac Cardiovasc Surg. 2008; 135 412-420
43 Ruiz R, Kunitake H, Wilkinson A H et al.. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg. 2006; 141 735-741 discussion 741-742
44 Pinderski L J, Kirklin J K, McGiffin D et al.. Multi-organ transplantation: is there a protective effect against acute and chronic rejection?. J Heart Lung Transplant. 2005; 24 1828-1833
45 Keenan R J, Bruzzone P, Paradis I L et al.. Similarity of pulmonary rejection patterns among heart-lung and double-lung transplant recipients. Transplantation. 1991; 51 176-180
46 Lau C L, Palmer S M, D'Amico T A, Tapson V F, Davis R D. Lung transplantation at Duke University Medical Center. Clin Transpl. 1998; 327-340
47 Vitulo P, Oggionni T, Cascina A et al.. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant. 2002; 21 435-439
48 Sarahrudi K, Estenne M, Corris P et al.. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg. 2004; 127 1126-1132
49 Shennib H, Massard G, Reynaud M, Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant. 1994; 13 514-519
50 Keenan R J, Iacono A, Dauber J H et al.. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 1997; 113 335-340 discussion 340-341
51 Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci. 2002; 26 197-204
52 Valentine V G, Robbins R C, Wehner J H, Patel H R, Berry G J, Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest. 1996; 109 1184-1189
53 Appel III J Z, Hartwig M G, Davis R D, Reinsmoen N L. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol. 2005; 66 378-386
54 Appel III J Z, Hartwig M G, Cantu III E, Palmer S M, Reinsmoen N L, Davis R D. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation. 2006; 81 1049-1057
55 Taylor C J, Smith S I, Morgan C H et al.. Selective omission of the donor cross-match before renal transplantation: efficacy, safety and effects on cold storage time. Transplantation. 2000; 69 719-723
56 Girnita A L, McCurry K R, Iacono A T et al.. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant. 2004; 23 1135-1141
57 Palmer S M, Davis R D, Hadjiliadis D et al.. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002; 74 799-804
58 Hadjiliadis D, Chaparro C, Reinsmoen N L et al.. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant. 2005; 24(7, Suppl) S249-S254
59 Burlingham W J, Love R B, Jankowska-Gan E et al.. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007; 117 3498-3506
60 Goers T A, Ramachandran S, Aloush A, Trulock E, Patterson G A, Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008; 180 4487-4494
61 Magro C M, Klinger D M, Adams P W et al.. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant. 2003; 3 1264-1272
62 Badesch D B, Zamora M, Fullerton D et al.. Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection. J Heart Lung Transplant. 1998; 17 415-422
63 Ionescu D N, Girnita A L, Zeevi A et al.. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol. 2005; 15 63-68
64 Miller G G, Destarac L, Zeevi A et al.. Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant. 2004; 4 1323-1330
65 Magro C M, Abbas A E, Seilstad K, Pope-Harman A L, Nadasdy T, Ross Jr P. C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction. Hum Immunol. 2006; 67 274-283
66 Westall G P, Snell G I, McLean C, Kotsimbos T, Williams T, Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant. 2008; 27 722-728
67 Wallace W D, Reed E F, Ross D, Lassman C R, Fishbein M C. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant. 2005; 24 1565-1570
68 Astor T L, Weill D, Cool C, Teitelbaum I, Schwarz M I, Zamora M R. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant. 2005; 24 2091-2097
69 Vo A A, Lukovsky M, Toyoda M et al.. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008; 359 242-251

Scott M PalmerM.D.

Duke University Medical Center, 106 Research Dr.

Bldg. MSRB2, Ste. 2073 (Box 103002), Durham, NC 27710

eMail: palme002@mc.duke.edu